Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates | 1 | Cision News | ||
Do | Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering | 1 | Cision News | ||
Do | LYTIX BIOPHARMA AS: Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity | 1 | Cision News | ||
Do | Lytix Biopharma AS: Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer representing a significant commercial opportunity. | 1 | Oslo Børs | ||
Mi | Lytix Biopharma AS - Preliminary results in the share offering | 1 | Cision News | ||
Mi | Lytix Biopharma AS - Last day of the Application Period | 1 | Cision News | ||
20.03. | Lytix Biopharma AS: Financial calendar | - | Oslo Børs | ||
26.01. | Lytix Biopharma AS: Financial calendar | - | Oslo Børs | ||
29.12.23 | Lytix Biopharma AS: Financial calendar | 1 | Oslo Børs | ||
09.11.23 | LYTIX BIOPHARMA AS: Lytix Biopharma presents third quarter 2023 results | 1 | Cision News | ||
08.11.23 | LYTIX BIOPHARMA AS: Lytix Biopharma presenting at major investor conferences in London and Stockholm in November | 1 | Cision News | ||
02.11.23 | LYTIX BIOPHARMA AS: Lytix Biopharma: Presentation of third quarter 2023 results, November 9 | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,160 | -4,98 % | Evotec-Aktie: Wann kommt die Trendwende? | Wenige Tage vor der Bekanntgabe neuer Geschäftszahlen kommt die Evotec-Aktie (WKN: 566480) ihrem 12-Monats-Tief, das bei 12,62 € liegt, gefährlich nahe. Während ein Analyst eine frische Kaufempfehlung... ► Artikel lesen | |
QIAGEN | 37,940 | -1,65 % | QIAGEN N.V.: QIAGEN erweitert Tuberkulose-Portfolio: Neues NGS-Panel unterstützt Echtzeit-Überwachung und Bekämpfung antimikrobieller Resistenzen | QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben // Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt... ► Artikel lesen | |
VERA THERAPEUTICS | 38,690 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
IMMUNOVANT | 27,750 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
KYMERA THERAPEUTICS | 33,350 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
ARCTURUS THERAPEUTICS | 26,170 | -3,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 44,200 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
ARCUTIS BIOTHERAPEUTICS | 8,590 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
DYNE THERAPEUTICS | 23,695 | -5,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 13,210 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
KEROS THERAPEUTICS | 54,19 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
SANA BIOTECHNOLOGY | 8,500 | -0,93 % | Sana Biotechnology, Inc. - 8-K, Current Report | ||
ARVINAS | 31,600 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |